NOVOB80 Stock Price and Chart — SET:NOVOB80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk (NOVO_B) is advancing its obesity drug, amycretin, to phase 3 trials in Q1 2026, showing a 22% weight loss in early tests. Market entry is expected by 2028.

Novo Nordisk is now Europe's most valuable company, with a market cap of $367.91 billion, following a 2.5% rise in shares due to its obesity drug amycretin's late-stage development.

Novo Nordisk signed an $812 million licensing deal with U.S. biotech Deep Apple for a weight-loss drug and announced a partnership with Septerna to develop oral small-molecule weight-loss drugs.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.